Theon International Plc (Euronext Amsterdam: THEON) closed at EUR 28.00 on October 21, 2026, about 27% below its August high, even after raising 2026 guidance to about EUR 600 million of revenue. Sean Westropp of Deep Sail Capital named Theon International a favorite long near its lows on October 22, calling it "NATO's night-vision franchise" with a new counter-drone business. The test is simple: Theon International needs about EUR 351 million of second-half revenue, and its Q3 trading update is expected around November 9, 2026.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Theon International Plc, THEON on Euronext Amsterdam; prices in euros.
- Situation type: a European defense supplier whose shares sold off while growing, now adding debt to buy into counter-drone systems.
- The call: Deep Sail Capital (@DeepSailCapital) is long and reiterated the view on October 22, 2026.
- Price: EUR 28.00 at the October 21, 2026 close, versus a closing high of EUR 38.32 on August 14, 2026 and a 52-week closing low of EUR 23.80 on November 26, 2025 (Yahoo Finance).
- First half 2026: revenue of EUR 248.7 million, up 35.4% (24.7% organic), with a 26.2% adjusted EBIT margin (company).
- The math: guidance of about EUR 600 million implies about EUR 351 million in the second half, 41% more than the first half, by our math.
- Main risk: leverage, which the company expects to rise to about 3.0x net debt to EBITDA after the roughly EUR 300 million HGH deal.
Is Theon International a good bet right now?
The bull case is that Theon International has a backlog that covers the guidance. The company reported a soft backlog of EUR 1,455.9 million at June 30, 2026, plus about EUR 902 million of customer options.
The bear case is timing and debt. The year depends on a heavy second half, and Theon International is funding the HGH acquisition entirely with borrowing. A late quarter or a delayed order would land on a more leveraged balance sheet.
Why are investors bullish on Theon International?
- Night vision demand. Night vision devices were 85.43% of first-half revenue, and NATO armies are re-equipping. Theon International announced about EUR 50 million of orders on September 30 and about EUR 45 million from two NATO members on October 20.
- Management's Outlook. Deputy CEO Philippe Mennicken said on October 20 that he expects order intake to accelerate toward year end and into the first quarter of 2027.
- Counter-drone entry. Theon International agreed in June to buy HGH Systemes Infrarouges, a French infrared maker, for an enterprise value of about EUR 300 million. The company said the deal marks its entry into counter-drone systems and should be mid-single-digit accretive to EPS in 2027.
- Margins. The adjusted EBIT margin rose to 26.2% from 25.8% a year earlier.
Who's making this call and why?
Sean Westropp runs Deep Sail Capital, a long/short growth and microcap fund, and posts as @DeepSailCapital. On September 30, 2026 he called Theon International a "European defense company, excellent management, focused on night vision but just bought a counter drone company." On October 22 he listed it among his favorite longs near a 52-week low and, asked for a thesis, replied that it is NATO's night-vision franchise that "just got into counter drones."
Track record. In our tracking, Deep Sail Capital is 13-12 (a .520 win rate) on 25 calls scored at 180 days against the S&P 500, with an average edge of +8.9 percentage points, ranked 6th on the career table. Its longs are 4-8 and its last 10 scored calls went 2-8. The September 30 Theon International call is too new to score; the stock is down 3.4% since then while the S&P 500 is up 1.1%, by our math. See the scoreboard.
Another supporter: Quartz Sea Research, which sells European defense research, argued on September 21 that Theon International's asset-light assembly model avoids the heavy factory spending of larger defense companies: "Theon International (THEON-NL) bypassed that capex trap entirely."
Who disagrees?
We found no detailed public short case. Signals on the other side:
- A known short seller. A post by ShortsInsights, which tracks the Dutch AFM short register, reported that Two Sigma held a 0.68% net short position on July 20, 2026.
- Rising debt. Greek outlet Dnews reported on the new EUR 325 million loan and management's estimate of about 3.0x pro forma leverage, falling toward 2.5x in 2027.
- Back-end loading. Second-half 2025 revenue was about EUR 259.7 million, so the EUR 351 million needed for 2026 is a 35% jump, by our math.
- Deal risk. Theon International said in July that it expects the HGH deal to close at the beginning of 2027, later than the fourth quarter of 2026 it first indicated.
What are the key facts to verify?
- The H1 2026 report release for revenue, margins, backlog, net debt and guidance.
- The semi-annual report for the night-vision revenue share.
- The HGH announcement and the July trading update for deal terms and timing.
- The October 20 order release.
What would prove it right or wrong?
Right: the Q3 update shows strong revenue and order intake, Theon International confirms about EUR 600 million for 2026, and options on the backlog are exercised.
Wrong: revenue slips into 2027, guidance is cut, the HGH deal stalls, or leverage stays near 3.0x longer than planned.
This is journalism and commentary, not investment advice. We hold no position unless stated.